Journal article

Visible Spectrophotometric Method for Quantitative Analysis of Sodium Valproate in Tablets

CGCristian-Catalin Gavat IGIrina Gradinaru AMAfrodita Doina Marculescu
Year2026
Volume143
Issue2
Pages281-292

Abstract

Sodium valproate is a first-line antiepileptic drug used mainly to treat epilepsy, as well as for bipolar disorder and migraine prevention and treatment. Valproate considerably increases the concentrations of gamma-aminobutyric acid in the brain, due to inhibition of enzymes responsible for the catabolism of this mediator. Main goal of this research consisted in the optimization and development of a new sensitive spectrophotometric method in the Visible field, for accurate quantitative analysis of sodium valproate in tablets. Following the diazotization and quantitative coupling color reaction of sodium valproate with diazonium salt of alpha naphthylamine 0.1% in alkaline medium, a light intense yellow azo dye was formed and spectrophotometrically analyzed at the wavelength of 406 nm. The content found of pure sodium valproate on pharmaceutical extended-release tablet was found to be 492.578 mg in relation to the stated pure amount of 500 mg sodium valproate on prolonged-release tablet. Determined content was assigned to 98.5156% pure sodium valproate in a pharmaceutical tablet and was found to be within the normal limits stated by European and International Pharmacopoeias rules, below 5% maximum allowed deviation according to the officialy stated amount of 500 mg. Average percentage deviation of the obtained amount from the officially stated value was 1.484%. Mentioned spectrophotometric method was then subjected to a statistical study consisting in the analysis of Linearity, Limit of detection (LOD), Limit of quantitation (LOQ), Pearson Correlation coefficient. All determined parameters had statistically accepted values.

Cite this article

Citation data